| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Epidemiology Biomarkers & Prevention, Vol 2, Issue 1 27-32, Copyright © 1993 by American Association for Cancer Research
ARTICLES |
AW Hsing and GW Comstock
National Cancer Institute, Division of Cancer Etiology, Bethesda, Maryland 20892.
A population-based nested case-control study was conducted to determine the relation of prediagnostic serum levels of testosterone, dihydrotestosterone, prolactin, follicle-stimulating hormone, luteinizing hormone, estrone, and estradiol to the risk of subsequent prostate cancer. Serum specimens of study subjects were available from a blood collection campaign in Washington County, Maryland, in 1974. Serum hormone levels of 98 histologically confirmed prostate cancer cases diagnosed in the subsequent 13 years were compared to those of 98 controls who were individually matched to cases on the basis of age (within weeks), sex, and race. There were no significant differences in levels of these hormones between cases and controls, although elevated levels of luteinizing hormone and of testosterone:dihydrotestosterone ratios were associated with mild increased risks of prostate cancer.
This article has been cited by other articles:
|
|
 |
|
  E. Hormones and Prostate Cancer Collaborative Group Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies J Natl Cancer Inst, February 6, 2008; 100(3): 170 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. R. Carpenter, W. R. Robinson, and P. A. Godley Getting Over Testosterone: Postulating a Fresh Start for Etiologic Studies of Prostate Cancer J Natl Cancer Inst, February 6, 2008; 100(3): 158 - 159. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Boger-Megiddo, N. S. Weiss, M. J. Barnett, G. E. Goodman, and C. Chen V89L Polymorphism of the 5{alpha}-Reductase Type II Gene (SRD5A2), Endogenous Sex Hormones, and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 286 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Wang, D. H. Catlin, B. Starcevic, D. Heber, C. Ambler, N. Berman, G. Lucas, A. Leung, K. Schramm, P. W. N. Lee, et al. Low-Fat High-Fiber Diet Decreased Serum and Urine Androgens in Men J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3550 - 3559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Parnes, I. M. Thompson, and L. G. Ford Prevention of Hormone-Related Cancers: Prostate Cancer J. Clin. Oncol., January 10, 2005; 23(2): 368 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chen, N. S. Weiss, F. Z. Stanczyk, S. K. Lewis, D. DiTommaso, R. Etzioni, M. J. Barnett, and G. E. Goodman Endogenous Sex Hormones and Prostate Cancer Risk: A Case-Control Study Nested within the Carotene and Retinol Efficacy Trial Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1410 - 1416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bhasin, A. B. Singh, R. P. Mac, B. Carter, M. I. Lee, and G. R. Cunningham Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan J Androl, May 1, 2003; 24(3): 299 - 311. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Taplin and S.-M. Ho The Endocrinology of Prostate Cancer J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477. [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Bosland Chapter 2: The Role of Steroid Hormones in Prostate Carcinogenesis J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 39 - 66. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
